10-Q · May 8, 2026
Femasys reported a notable rebound in Q1 2026 with revenue reaching $424,889, a 24.5% increase from the prior year. The company's net income turned positive at $846,100, reflecting a significant improvement over the…
Earnings analysis · 10-Q
FEMY earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Femasys reported Q2 2026 revenue of $331,827, down 18.9% year over year and approximately 21.9% sequentially, while diluted EPS improved to $(1.33) from $(3.18) in the prior-year quarter. A roughly $30.0 million…
Read full summary
Femasys reported Q2 2026 revenue of $331,827, down 18.9% year over year and approximately 21.9% sequentially, while diluted EPS improved to $(1.33) from $(3.18) in the prior-year quarter. A roughly $30.0 million financing and a 25.7% reduction in six-month R&D expense support liquidity and cost control, but ongoing losses, approximately negative $4 million of quarterly free cash flow, and weak revenue keep sentiment neutral. The 10-Q provided no quantitative revenue or EPS guidance and disclosed no material changes to previously reported risk factors as of August 14, 2026.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.33
- Segment
- Single reportable segment: revenue of $331,827
What stood out
-
Revenue declined year over year and sequentially
Second-quarter revenue was $331,827, down 18.9% year over year and approximately 21.9% sequentially from $424,889 in Q1 2026.
-
Per-share loss improved materially
Diluted EPS improved to $(1.33) from $(3.18) in Q2 2025, a $1.85 per-share improvement.
-
Six-month R&D expense decreased
Six-month research and development expense declined 25.7% year over year, indicating lower clinical development spending.
-
Approximately $30 million financing completed
The company completed financing of approximately $30.0 million, improving near-term liquidity resources.
-
Disclosure controls remained effective
Management concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026.
What to watch
-
Commercial traction remains weak
Revenue of $331,827 was down 18.9% year over year, highlighting commercialization and demand-execution risk.
-
Continued losses and cash burn
Quarterly diluted EPS was $(1.33), and free cash flow was approximately negative $4 million in the latest reported quarter, indicating continued cash-burn risk.
-
Clinical and regulatory risks persist
The filing states there were no material changes to previously disclosed risk factors as of August 14, 2026; therefore, the principal clinical, regulatory and financing risks remain unchanged rather than resolved.
Management's outlook
No quantitative revenue or EPS guidance was provided in the filing; outlook deferred to the earnings release or call.
Earlier filings 4
10-K · March 31, 2026
Femasys reported full-year 2025 revenue of $2,293,313 with sequential acceleration in H2 (Q3 $729,394; Q4 $813,387) driven by commercial expansion and regulatory milestones for FemBloc and FemaSeed. The company remains…
10-Q · August 8, 2025
Femasys reported Q2 sales of $409,268 and GAAP net loss per share of $(0.16). Revenue increased versus the prior-year quarter ($221,484 in Q2 2024) and gross margin remained healthy at 61.4%, but the company generated…
10-K · March 27, 2025
Femasys’ 10-K highlights material commercial and regulatory progress (CE mark for the FemBloc delivery system in March 2025; pivotal and peer‑reviewed clinical data for FemaSeed and FemBloc) while the company remains…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.